Home » PREOTACT APPROVED IN EUROPE
PREOTACT APPROVED IN EUROPE
NPS Pharmaceuticals and its partner Nycomed have received market authorization from the European Medicines Evaluation Agency (EMEA) for Preotact (parathyroid hormone [rDNA origin] for injection).
Preotact is approved to treat postmenopausal women at risk of bone fractures from osteoporosis. The company plans to begin shipping the drug later this year.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May